Skip to content
value.today
Kempharm Inc. logo

Kempharm Inc.

🇺🇸 North Liberty, Iowa, USAPharmaceuticalsFounded 2006
Total raised
$14 M
3 rounds on record
Latest round
$4 M
Feb 2015
First round on record
Apr 2009
Today
Went public
See the company page

Kempharm Inc. is listed today as Zevra Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Kempharm Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2021$39 MPrivate placement after listing$10 to $50 million

Kempharm Inc.: Private sale, Jun 2021

Investors in this round

12 investors had bought by the notice of Jun 22, 2021: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Kempharm Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$39 M of $39 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,345,912
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • R. LaDuane Clifton · Executive Officer
  • Sven LaDuane Guenther · Executive Officer
  • Timothy J. Sangiovanni · Executive Officer
  • Travis C. Mickle · Executive Officer, Director, Promoter
  • David S. Tierney · Director
  • Joseph B. Saluri · Director
  • Matthew R. Plooster · Director
  • Richard W. Pascoe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in CA, CT, MA, NJ, NY

Signed by R. LaDuane Clifton, CFO, Treas & Sec. Source: SEC Form D, newest notice filed Jun 22, 2021. Read the notice at the SEC.

optionsSEC
Jan 2021$44 MPrivate placement after listing$10 to $50 million

Kempharm Inc.: Private sale, Jan 2021

Investors in this round

15 investors had bought by the notice of Feb 4, 2021: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Kempharm Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$44 M of $44 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,641,523
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • R. LaDuane Clifton · Executive Officer
  • Sven LaDuane Guenther · Executive Officer
  • Timothy J. Sangiovanni · Executive Officer
  • Travis C. Mickle · Executive Officer, Director, Promoter
  • David S. Tierney · Director
  • Joseph B. Saluri · Director
  • Matthew R. Plooster · Director
  • Richard W. Pascoe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in CA, CT, MA, NJ, NV, NY

Signed by R. LaDuane Clifton, CFO, Treas & Sec. Source: SEC Form D, newest notice filed Feb 4, 2021. Read the notice at the SEC.

optionsSEC
Jan 2021$31 MPrivate placement after listing$10 to $50 million

Kempharm Inc.: Private sale, Jan 2021

Investors in this round

4 investors had bought by the notice of Jan 13, 2021: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Kempharm Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$2,000,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • R. LaDuane Clifton · Executive Officer
  • Sven LaDuane Guenther · Executive Officer
  • Timothy J. Sangiovanni · Executive Officer
  • Travis C. Mickle · Executive Officer, Director, Promoter
  • David S. Tierney · Director
  • Joseph B. Saluri · Director
  • Matthew R. Plooster · Director
  • Richard W. Pascoe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cowen & Company, LLC (CRD 7616) · New York, New YorkSold in IL, NY

Remarks in the notice

  • On the amounts: “Securities issued in the offering include shares of Series B-2 Preferred Stock and warrants to purchase common stock. Securities were issued in exchange for a portion of the principal amount of outstanding convertible promissory notes.”

Signed by R. LaDuane Clifton, CFO, Treas & Sec. Source: SEC Form D, newest notice filed Jan 13, 2021. Read the notice at the SEC.

equity, optionsSEC
Oct 2018$1 MPrivate placement after listingUnder $2 million

Kempharm Inc.: Private sale, Oct 2018

Investors in this round

1 investor had bought by the notice of Nov 2, 2018: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Kempharm Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gordon K. Johnson · Executive Officer
  • R. LaDuane Clifton · Executive Officer
  • Sven K. Guenther · Executive Officer
  • Timothy J. Sangiovanni · Executive Officer
  • Travis C. Mickle · Executive Officer, Director, Promoter
  • Danny L. Thompson · Director
  • David S. Tierney · Director
  • Joseph B. Saluri · Director
  • Matthew R. Plooster · Director
  • Richard W. Pascoe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by R. LaDuane Clifton, CFO, Treas & Sec. Source: SEC Form D, newest notice filed Nov 2, 2018. Read the notice at the SEC.

optionsSEC
Feb 2015$4 MNo. 3$2 to $10 million

Kempharm Inc.: Raise no. 3, Feb 2015

Investors in this round

1 investor had bought by the notice of Mar 4, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Kempharm Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christal M.M. Mickle · Executive Officer, Director
  • Gordon K. Johnson · Executive Officer
  • Sven Guenther · Executive Officer, Director
  • Tracy M. Woody · Executive Officer
  • Travis C. Mickle · Executive Officer, Director, Promoter
  • Danny L. Thompson · Director
  • David S. Tierney · Director
  • Jonathan S. Leff · Director
  • Joseph B. Saluri · Director
  • Matthew R. Plooster · Director
  • Richard W. Pascoe · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Gordon K. Johnson, Chief Operating Officer and Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 4, 2015. Read the notice at the SEC.

equitySEC
Jul 2010$7 MNo. 2$2 to $10 million

Kempharm Inc.: Raise no. 2, Jul 2010

Investors in this round

216 investors had bought by the notice of Jun 30, 2011: 215 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Kempharm Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $25 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$2,125,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Iowa

People named in the notice

  • Christal M.M. Mickle · Executive Officer, Director
  • Kathleen H. Holt · Executive Officer
  • Sven J. Guenther · Executive Officer
  • Todd J. Johnson · Executive Officer, Director
  • Travis C. Mickle · Executive Officer, Director, Promoter
  • Adam J. Claypool · Director
  • Danny J. Thompson · Director
  • Matt J. Plooster · Director
  • Todd J. Doorenbos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Adam Stone Claypool (CRD 2572486) · broker-dealer DeWaay Financial Network, LLC (CRD 30767) · Clive, IowaSold in all US states

Remarks in the notice

  • On fees: “Reduced cash comm. is paid for shares sold to affiliates. Plcmt Agt receives warrant to purchase shares of Class A Common Stock equal to 15.0% of the Common Stock shares issuable upon conversion into Common Stock of Shares subscribed in this offering.”

Signed by Travis Mickle, President. Source: SEC Form D, newest notice filed Jun 30, 2011. Read the notice at the SEC.

equitySEC
Apr 2009$3 MNo. 1$2 to $10 million

Kempharm Inc.: Raise no. 1, Apr 2009

Investors in this round

134 investors had bought by the notice of Aug 27, 2009: 134 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for Kempharm Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $4 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$170,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Iowa

People named in the notice

  • Christal Mickle · Executive Officer, Director
  • Robert Karr · Executive Officer, Director
  • Travis Mickle · Executive Officer, Director, Promoter
  • Adam Claypool · Director
  • Dan Thompson · Director
  • Robert Beardsley · Director
  • Todd Johnson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Adam Stone Claypool (CRD 2572486) · broker-dealer DeWaay Financial Network, LLC (CRD 30767) · Clive, IaSold in all US states

Remarks in the notice

  • On fees: “The maximum sales commission which may be payable is $327,794, together with a warrant for class A common stock, the value of which cannot be determined at this time.”

Signed by Travis Mickle, President. Source: SEC Form D, newest notice filed Aug 27, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Zevra Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: MIPLYFFA $87.40 million (82%), OLPRUVA $800,000 (1%).

    Annual report (SEC XBRL) · Dec 2025

  • Kempharm Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2021).

    SEC Form D · Jun 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2021

Products and services#

No products or services of Kempharm Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in Kempharm Inc.
InvestorKindAmountRoundRoleSource
Christal M. M. MicklePersonnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Danny L. ThompsonPersonnot statednot statedHeld Series A, B and C preferred stock, director (Form 3, 2015)SEC Form 3
Joseph SaluriPersonnot statednot statedHeld Series B and C preferred stock, director (Form 3, 2015)SEC Form 3
Matthew R. PloosterPersonnot statednot statedHeld Series C and D preferred stock, director (Form 3, 2015)SEC Form 3
Sven GuentherPersonnot statednot statedHeld Series A, B and C preferred stock (Form 3, 2015)SEC Form 3
Travis C. MicklePersonnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner, director (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 216 investors.

Largest shareholders today

Institutions holding Zevra Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Kempharm Inc.
NameRoleNamed in
R. LaDuane CliftonExecutive officerJun 2021
Sven LaDuane GuentherExecutive officerJun 2021
Timothy J. SangiovanniExecutive officerJun 2021
Travis C. MickleExecutive officerJun 2021
Gordon K. JohnsonExecutive officerNov 2018
Sven K. GuentherExecutive officerNov 2018
Christal M.M. MickleExecutive officerMar 2015
Sven GuentherExecutive officerMar 2015
Tracy M. WoodyExecutive officerMar 2015
Kathleen H. HoltExecutive officerJun 2011
Sven J. GuentherExecutive officerJun 2011
Todd J. JohnsonExecutive officerJun 2011
Christal MickleExecutive officerAug 2009
Robert KarrExecutive officerAug 2009
Travis MickleExecutive officerAug 2009
David S. TierneyDirectorJun 2021
Joseph B. SaluriDirectorJun 2021
Matthew R. PloosterDirectorJun 2021
Richard W. PascoeDirectorJun 2021
Travis C. MickleDirectorJun 2021
Danny L. ThompsonDirectorNov 2018
Christal M.M. MickleDirectorMar 2015
Jonathan S. LeffDirectorMar 2015
Sven GuentherDirectorMar 2015
Adam J. ClaypoolDirectorJun 2011
Danny J. ThompsonDirectorJun 2011
Matt J. PloosterDirectorJun 2011
Todd J. DoorenbosDirectorJun 2011
Todd J. JohnsonDirectorJun 2011
Adam ClaypoolDirectorAug 2009
Christal MickleDirectorAug 2009
Dan ThompsonDirectorAug 2009
Robert BeardsleyDirectorAug 2009
Robert KarrDirectorAug 2009
Todd JohnsonDirectorAug 2009
Travis MickleDirectorAug 2009
Travis C. MicklePromoterJun 2021
Travis MicklePromoterAug 2009

Went public since 2015. Its SEC number is that of a company listed on a stock exchange.